ReviewMicrobiologyOpen2026
Mechanisms and Application of Bacteriophages in Regulating Intestinal Health of Livestock and Poultry.
Review in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The escalating crisis of antibiotic resistance has driven the global livestock and poultry industry to seek effective alternatives. Bacteriophages (phages) are promising candidates because their high host specificity allows targeted elimination of key intestinal pathogens, including Salmonella, Campylobacter, pathogenic Escherichia coli, and Clostridium perfringens, while sparing commensal microbiota. This review summarizes the mechanisms by which phages promote intestinal health in livestock and poultry, covering pathogen lysis, modulation of gut microbiota, reinforcement of the intestinal mucosal barrier, and regulation of host immune responses. Evidence from broiler chickens, weaned piglets, and ruminants shows that phage therapy can improve growth performance and help control diseases such as necrotic enteritis and edema disease. We further discuss how administration route, dosage, timing, and formulation affect intestinal delivery, and how encapsulation systems such as microcapsules and liposomes improve phage survival under gastrointestinal conditions. Strategies to delay resistance evolution through phage cocktails, and combinations of phages with probiotics or plant extracts, are also evaluated, with a staged screening framework proposed for assessing compatibility prior to field deployment. Because positive results dominate the controlled-trial literature, we critically appraise failed, limited, and non-durable in vivo trials, attributing these outcomes to rapid clearance, anti-phage immunity, inappropriate dosing, and spatial exclusion coupled with ecological mismatch. Commercial translation additionally depends on scalable production and downstream removal of endotoxins and host cell proteins at acceptable cost. Overcoming these challenges would allow phage-based interventions to serve as precision antibiotic alternatives that support sustainable animal farming and global food security.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.